ArticleVeterinary world2025
Short-term consequences of daily consumption of the quinoa (
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Materials and Methods: Forty-eight adult male Wistar rats were randomly assigned to eight groups (n = 6 each) based on diabetic status and dietary quinoa concentration. Diabetes was induced using low-dose STZ (25 mg/kg). Animals received the respective quinoa-enriched diets for 30 days. Blood glucose, glycated hemoglobin, lipid profiles, liver/kidney function markers, and complete blood counts were analyzed. Histological assessments of liver and kidney tissues were also performed. Results: Diabetic rats receiving 40% and 80% quinoa diets exhibited significant reductions in fasting blood glucose (p < 0.05) and alanine transaminase levels (p < 0.01), indicating improved glycemic and hepatic function. Very low-density lipoprotein cholesterol decreased significantly in all quinoa-fed diabetic groups, and high-density lipoprotein cholesterol increased notably in the 20% quinoa group (p < 0.05). Normal rats showed no adverse changes across biochemical or hematological indices. Histological analysis confirmed the absence of morphological abnormalities in hepatic and renal tissues in all groups. Conclusion: Short-term dietary quinoa supplementation, particularly at 40% and 80% inclusion levels, effectively improves glycemic and lipid profiles and mitigates liver enzyme elevations in diabetic rats without compromising health parameters in normal controls. The findings support quinoa's potential as a safe dietary adjunct in managing diabetes-related metabolic dysfunctions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.